IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
IGC Pharma (NYSE American:IGC) has received a Notice of Allowance from the USPTO for patent application US 17/613,909 (IGC510), covering a novel treatment method using THC and/or CBD for stammering, stuttering, and Tourette's syndrome. The therapeutic approach combines microdoses of THC with atypical antipsychotics to target the endocannabinoid system.
The treatment aims to serve an estimated 75 million people globally affected by these conditions. The patent adds to IGC's portfolio, which includes treatments for Alzheimer's, pain, and eating disorders. The company plans to develop clinical formulations similar to their flagship medication IGC-AD1, currently in Phase 2 CALMA clinical trials.
IGC Pharma (NYSE American:IGC) ha ricevuto una Notice of Allowance dall'USPTO per la domanda di brevetto US 17/613,909 (IGC510), che riguarda un nuovo metodo terapeutico basato su THC e/o CBD per la balbuzie, lo stentare e la sindrome di Tourette. L'approccio terapeutico prevede la combinazione di microdosi di THC con antipsicotici atipici per modulare il sistema endocannabinoide.
Il trattamento è pensato per raggiungere circa 75 milioni di persone nel mondo affette da queste condizioni. Il brevetto si aggiunge al portafoglio di IGC, che include terapie per l'Alzheimer, il dolore e i disturbi alimentari. L'azienda intende sviluppare formulazioni cliniche simili al suo farmaco di punta IGC-AD1, attualmente in studi clinici di Fase 2 CALMA.
IGC Pharma (NYSE American:IGC) ha recibido una Notice of Allowance de la USPTO para la solicitud de patente US 17/613,909 (IGC510), que cubre un nuevo método de tratamiento con THC y/o CBD para la tartamudez, el balbuceo y el síndrome de Tourette. El enfoque terapéutico combina microdosis de THC con antipsicóticos atípicos para actuar sobre el sistema endocannabinoide.
El tratamiento pretende beneficiar a unas 75 millones de personas en todo el mundo afectadas por estas condiciones. La patente se suma al portafolio de IGC, que incluye tratamientos para el Alzheimer, el dolor y los trastornos alimentarios. La compañía planea desarrollar formulaciones clínicas similares a su medicamento principal IGC-AD1, actualmente en los ensayos clínicos de Fase 2 CALMA.
IGC Pharma (NYSE American:IGC)가 USPTO로부터 특허 출원 US 17/613,909(IGC510)에 대한 Notice of Allowance를 받았습니다. 해당 특허는 말더듬(스태머링/스토터링) 및 투렛 증후군에 대한 THC 및/또는 CBD를 이용한 새로운 치료법을 다룹니다. 치료법은 THC 마이크로도스와 비정형 항정신병약의 병용으로 내인성 칸나비노이드 계통을 표적화합니다.
이 치료는 이러한 질환으로 고통받는 전 세계 약 7,500만 명을 대상으로 합니다. 이번 특허는 알츠하이머, 통증, 섭식장애 치료제를 포함한 IGC의 포트폴리오에 추가됩니다. 회사는 현재 Fase 2 CALMA 임상시험 중인 대표 약물 IGC-AD1과 유사한 임상 제형을 개발할 계획입니다.
IGC Pharma (NYSE American:IGC) a reçu une Notice of Allowance de l'USPTO pour la demande de brevet US 17/613,909 (IGC510), couvrant une nouvelle méthode de traitement par THC et/ou CBD pour le bégaiement, le balbutiement et le syndrome de Tourette. L'approche thérapeutique associe des microdoses de THC à des antipsychotiques atypiques pour cibler le système endocannabinoïde.
Le traitement vise à concerner environ 75 millions de personnes dans le monde touchées par ces troubles. Le brevet vient s'ajouter au portefeuille d'IGC, qui comprend des traitements pour la maladie d'Alzheimer, la douleur et les troubles du comportement alimentaire. La société prévoit de développer des formulations cliniques similaires à son médicament phare IGC-AD1, actuellement en essais cliniques de phase 2 CALMA.
IGC Pharma (NYSE American:IGC) hat vom USPTO eine Notice of Allowance für die Patentanmeldung US 17/613,909 (IGC510) erhalten, die ein neuartiges Behandlungsverfahren mit THC und/oder CBD gegen Stottern, Stammern und das Tourette-Syndrom abdeckt. Der therapeutische Ansatz kombiniert Mikrodosen von THC mit atypischen Antipsychotika, um das Endocannabinoid-System zu adressieren.
Die Behandlung richtet sich an schätzungsweise 75 Millionen Menschen weltweit, die von diesen Störungen betroffen sind. Das Patent ergänzt IGCs Portfolio, das Therapien für Alzheimer, Schmerz und Essstörungen umfasst. Das Unternehmen plant, klinische Formulierungen zu entwickeln, die ihrem Flaggschiff-Medikament IGC-AD1 ähneln, das derzeit in der Phase-2 CALMA-Studie erprobt wird.
- Receipt of USPTO Notice of Allowance strengthens intellectual property portfolio
- Treatment targets a large market of 75 million affected individuals globally
- Microdose approach may offer improved safety profile compared to traditional treatments
- Expands company's patent portfolio alongside treatments for Alzheimer's, pain, and eating disorders
- Patent still requires final documentation and fee payment to complete the process
- Clinical trials and FDA approval still needed before commercialization
Insights
IGC Pharma's patent allowance for THC microdose treatment strengthens IP portfolio with potential for addressing 75M patient market.
IGC Pharma has received a Notice of Allowance from the USPTO for patent application US 17/613,909 (IGC510), representing a significant intellectual property milestone. This patent covers a proprietary method for treating stammering, stuttering, and Tourette's syndrome using THC and/or CBD, targeting a substantial global market of approximately 75 million affected individuals.
The therapeutic approach combines microdoses of THC with low doses of atypical antipsychotics, specifically designed to target the endocannabinoid system. This strategy aims to optimize efficacy while minimizing the adverse effects typically associated with higher doses of either compound alone.
This allowance strategically expands IGC's intellectual property portfolio, which already includes patents for Alzheimer's, pain management, and eating disorders. The company plans to advance this research toward clinical formulations following a similar development path as their flagship product IGC-AD1, which is currently in Phase 2 clinical trials (CALMA).
The microdosing approach is particularly notable as it addresses a critical safety concern with cannabis-based therapeutics. By using minimal effective doses of THC, IGC510 aims to deliver therapeutic benefits while maintaining a more favorable safety profile than traditional high-dose THC or antipsychotic treatments.
For IGC Pharma, this patent allowance represents not just protection for a novel formulation but potential positioning in multiple neurological disorder markets where current treatment options are limited or carry significant side effect burdens.
POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome with THC and/or CBD.
A notice of allowance ("NOA") for a patent application means that claims have been allowed and the applicant must submit formal documents and pay the issue fees to complete the process. Globally, an estimated 75 million people are affected by stuttering, stammering, or Tourette syndrome. THC (Tetrahydrocannabinol) and CBD (cannabidiol) are two primary cannabinoids of the cannabis plant, with THC being known for its psychoactive properties. Our therapeutic approach combines low doses of atypical antipsychotics with low doses of THC, designed to target the endocannabinoid system. This approach aims to improve treatment effectiveness in Tourette's syndrome, stuttering, and stammering, while reducing the side effects typically associated with high-dose THC or antipsychotic treatments.
"Securing this NOA adds to our growing IP portfolio, that includes patents for Alzheimer's, pain, eating disorders among others, many of which contain low doses of THC. We plan to move the research to clinical formulations similar to IGC-AD1 our flag ship medication that also contains low doses of THC and is in the CALMA Phase 2 clinical trials", said Ram Mukunda, Chief Executive Officer of IGC Pharma. "By focusing on microdoses, IGC510 has the potential to address a critical unmet need for patients suffering from stammering, stuttering, and Tourette's syndrome with a safer therapeutic profile."
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 active patent filings, 12 granted patents, and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What patent did IGC Pharma receive approval for in August 2025?
How many people could potentially benefit from IGC's new treatment?
What is unique about IGC Pharma's treatment approach for Tourette's and stuttering?
What is the current status of IGC-AD1, IGC Pharma's flagship medication?
What other conditions does IGC Pharma have patents for?
